Home | About CDC | Press Room | Funding | A-Z Index | Centers, Institute & Offices | Training & Employment | Contact Us
CDC Centers for Disease Control and Prevention Home Page
_
_  
Search: 
 
_
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
_
Severe Acute Respiratory Syndrome (SARS)

Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) Version 2

Supplement F: Laboratory Guidance

Summary
May 3, 2005

Download PDF version formatted for print Adobe Acrobat Reader (53 KB/ 2 pages)
Download Word version formatted for print Microsoft Word (352 KB/ 2 pages)

Goals

  • Provide the public health community with ready access to high-quality SARS-CoV diagnostics.
  • Ensure that SARS-CoV laboratory diagnostics are used safely and appropriately and that results are interpreted appropriately.
Key concepts
  • Efficient SARS-CoV diagnostic assays have been developed, but they frequently do not provide a definitive diagnosis early in illness.
  • Although the sensitivity of current assays probably cannot be improved significantly, changes in the type, quality, and processing of specimens may improve the ability to detect SARS-CoV infection in patients.
  • The majority of SARS-like illnesses will be caused by other respiratory pathogens; rapid and accurate diagnosis of these infections will make it easier to manage community anxiety about SARS-like illnesses.
  • The possibility of false-positive and false-negative results with both PCR and serologic assays should always be considered when interpreting results; clear strategies to minimize such possibilities and to confirm test results are essential.
Priority activities
  • Improve the ability to detect SARS-CoV infection by optimizing the selection and timing of specimen collection and processing.
  • Provide SARS-CoV assays for RT-PCR testing to Laboratory Response Network (LRN) laboratories and for serologic testing to state public health laboratories.
  • Distribute proficiency panels and questionnaires to participating laboratories to determine the ability of laboratories to provide valid SARS-CoV diagnostics.
  • Provide guidance on laboratory safety for SARS-CoV and other respiratory diagnostic testing and for possible SARS-CoV-containing specimens submitted for other tests.
  • Provide guidance for interpreting test results, taking into account the potential for false-positive and false-negative results and the availability of applicable clinical and epidemiologic information.
  • Identify surge capacity for laboratory testing in the event of a large SARS outbreak.

 

_
_
Topic Contents
_ arrow SARS Home
  arrow Community Containment
  arrow Evaluation/Diagnosis
  arrow Exposure Management
  arrow Infection Control
  arrow Laboratory
  arrow Legal Authorities
  arrow Preparedness Planning
  arrow References & Resources
  arrow Surveillance & Reporting
  arrow Travel
  arrow What Everyone Should Know
  arrow What's New
_
_
blackdots
_

Contact Info

Public:
English 800-CDC-INFO
Español 888-246-2857
TTY 888-232-6348
Clinician:
English 877-554-4625
_
arrow Sign up for the Clinician Registry
arrow Contact Us
_
blackdots
_
    Home   |   Policies and Regulations   |   Disclaimer   |   e-Government   |  FOIA   |  Contact Us  
Safer, Healthier People FirstGovDHHS Department of Health
and Human Services
Centers for Disease Control and Prevention,1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (800) CDC-INFO